Literature DB >> 11386751

Intragenic deletions at Atp7a in mouse models for Menkes disease.

P Cunliffe1, V Reed, Y Boyd.   

Abstract

Mottled mice have mutations in the copper-transporting ATPase Atp7a. They are proven models for the human disorder Menkes disease (MD), which results from mutations in a homologous gene. Mottled mice can be divided into three classes: class 1, in which affected males die before birth; class 2, in which affected males die in the early postnatal period; and class 3, in which affected males survive to adulthood. In humans, it has been shown that mutations that lead to a complete absence of functional protein cause classical MD, which is characterized by death of boys in early childhood. We hypothesized that the most severely affected mottled alleles would be the most likely to carry mutations equivalent to those causing classical MD and therefore undertook mutational analysis of several class 1 mottled alleles to assess whether these were appropriate models for the disease at the molecular level. Two novel mutations, a deletion of exons 11-14 in mottled spot and an insertion in exon 10 leading to missplicing in mottled candy, were identified. However, these are both "in-frame" mutations, as are the other eight Atp7a mutations reported to date, and therefore no frameshift or nonsense mutations have yet been associated with the mottled phenotype. This contrasts with the mutation spectrum associated with MD, emphasizing the need for caution when mottled mice are used as models for the clinical disorder. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11386751     DOI: 10.1006/geno.2001.6529

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  8 in total

Review 1.  Menkes disease.

Authors:  Zeynep Tümer; Lisbeth B Møller
Journal:  Eur J Hum Genet       Date:  2009-11-04       Impact factor: 4.246

Review 2.  ATP7A-related copper transport diseases-emerging concepts and future trends.

Authors:  Stephen G Kaler
Journal:  Nat Rev Neurol       Date:  2011-01       Impact factor: 42.937

3.  A novel active L1 retrotransposon subfamily in the mouse.

Authors:  J L Goodier; E M Ostertag; K Du; H H Kazazian
Journal:  Genome Res       Date:  2001-10       Impact factor: 9.043

4.  Interactions of peptide amidation and copper: novel biomarkers and mechanisms of neural dysfunction.

Authors:  Danielle Bousquet-Moore; Joseph R Prohaska; Eduardo A Nillni; Traci Czyzyk; William C Wetsel; Richard E Mains; Betty A Eipper
Journal:  Neurobiol Dis       Date:  2009-10-06       Impact factor: 5.996

Review 5.  Animal Models of Normal and Disturbed Iron and Copper Metabolism.

Authors:  Xiaoyu Wang; Michael D Garrick; James F Collins
Journal:  J Nutr       Date:  2019-12-01       Impact factor: 4.798

6.  Heritable L1 retrotransposition in the mouse primordial germline and early embryo.

Authors:  Sandra R Richardson; Patricia Gerdes; Daniel J Gerhardt; Francisco J Sanchez-Luque; Gabriela-Oana Bodea; Martin Muñoz-Lopez; J Samuel Jesuadian; Marie-Jeanne H C Kempen; Patricia E Carreira; Jeffrey A Jeddeloh; Jose L Garcia-Perez; Haig H Kazazian; Adam D Ewing; Geoffrey J Faulkner
Journal:  Genome Res       Date:  2017-05-08       Impact factor: 9.043

Review 7.  Mottled Mice and Non-Mammalian Models of Menkes Disease.

Authors:  Małgorzata Lenartowicz; Wojciech Krzeptowski; Paweł Lipiński; Paweł Grzmil; Rafał Starzyński; Olga Pierzchała; Lisbeth Birk Møller
Journal:  Front Mol Neurosci       Date:  2015-12-18       Impact factor: 5.639

8.  L1 retrotransposition is a common feature of mammalian hepatocarcinogenesis.

Authors:  Stephanie N Schauer; Patricia E Carreira; Ruchi Shukla; Daniel J Gerhardt; Patricia Gerdes; Francisco J Sanchez-Luque; Paola Nicoli; Michaela Kindlova; Serena Ghisletti; Alexandre Dos Santos; Delphine Rapoud; Didier Samuel; Jamila Faivre; Adam D Ewing; Sandra R Richardson; Geoffrey J Faulkner
Journal:  Genome Res       Date:  2018-04-11       Impact factor: 9.043

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.